https://mindmedicinelaw.com/briefing/fda-sets-approval-pathway-for-psilocybin-and-lsd-therapies-20261004-46886The Psychedelic Journalen2026-10-04T22:03:28.759323+00:00FDA Sets Approval Pathway for Psilocybin and LSD Therapiesfda, psilocybin, lsd, psychedelic approval, drug policy, breakthrough therapy, clinical trials, controlled substances act, risk management, digital health toolshttps://mindmedicinelaw.com/briefing/modest-antisuicidal-effects-from-repeated-ketamine-in-trd-no-biomarker-breakthro-20261002-46341The Psychedelic Journalen2026-10-03T15:05:37.268342+00:00Modest Antisuicidal Effects from Repeated Ketamine in TRD: No Biomarker Breakthroughketamine, treatment-resistant depression, suicidal ideation, biomarkers, clinical trials, plasma biomarkers, open-label study, psychiatric research, antisuicidal effectshttps://mindmedicinelaw.com/briefing/behavioral-state-confounds-eeg-biomarkers-in-preclinical-rat-studies-20261001-46619The Psychedelic Journalen2026-10-04T15:06:24.969250+00:00Behavioral State Confounds EEG Biomarkers in Preclinical Rat Studiespreclinical eeg, behavioral confound, psychedelic research, rat neurophysiology, biomarker validity, standardization, translational neuroscience, functional connectivity, drug developmenthttps://mindmedicinelaw.com/briefing/glpg3970-sik2-3-inhibitor-antidepressant-effects-in-preclinical-models-20261001-46665The Psychedelic Journalen2026-10-04T15:06:13.466611+00:00GLPG3970 SIK2/3 Inhibitor: Antidepressant Effects in Preclinical Modelsglpg3970, sik2/3 inhibitor, antidepressant mechanism, bdnf signaling, hippocampal neurogenesis, preclinical depression models, psychedelic research, novel antidepressants, neuroplasticity, clinical trial pipelinehttps://mindmedicinelaw.com/briefing/ethical-and-epistemic-risks-in-psychedelic-therapy-us-clinical-practice-20261001-46615The Psychedelic Journalen2026-10-04T15:05:45.104341+00:00Ethical and Epistemic Risks in Psychedelic Therapy: US Clinical Practicepsychedelic-assisted therapy, epistemic discipline, clinical ethics, memory reliability, trauma survivors, sexual abuse, training standards, credentialing, authority dynamics, us clinical practicehttps://mindmedicinelaw.com/briefing/therapist-psychedelic-experience-participant-preferences-in-us-psilocybin-trials-20261001-46620The Psychedelic Journalen2026-10-04T15:05:26.329941+00:00Therapist Psychedelic Experience: Participant Preferences in US Psilocybin Trialspsilocybin-assisted psychotherapy, therapist qualifications, participant preferences, clinical trial ethics, psychedelic research, therapist disclosure, bias in clinical trials, FDA guidance, training standardshttps://mindmedicinelaw.com/briefing/new-mexico-s-medical-psilocybin-act-first-statewide-clinician-program-20261001-46617The Psychedelic Journalen2026-10-04T15:05:11.428757+00:00New Mexico’s Medical Psilocybin Act: First Statewide Clinician Programnew mexico psilocybin act, medical psilocybin program, psychedelic policy united states, clinician-governed access, psilocybin regulation, equity in psychedelic care, state vs federal law, psychedelic clinical trialshttps://mindmedicinelaw.com/briefing/psilocybin-and-embeddedness-new-human-study-expands-mechanistic-insights-20261001-46514The Psychedelic Journalen2026-10-03T22:04:17.140346+00:00Psilocybin and 'Embeddedness': New Human Study Expands Mechanistic Insightspsilocybin, embeddedness, self-perception, default mode network, clinical trial endpoints, psychedelic neuroscience, regulatory science, therapeutic models, subjective experiencehttps://mindmedicinelaw.com/briefing/neurospirituality-in-clinical-neuroscience-evidence-gaps-and-implications-20261001-46297The Psychedelic Journalen2026-10-03T15:05:58.804547+00:00Neurospirituality in Clinical Neuroscience: Evidence, Gaps, and Implicationsneurospirituality, spirituality and neuroscience, clinical trials, palliative care, default mode network, psychedelic research, meaning-making, regulatory science, existential well-beinghttps://mindmedicinelaw.com/briefing/scientific-vs-legal-definitions-of-drug-and-narcotic-drug-20260930-46624The Psychedelic Journalen2026-10-04T15:06:52.571851+00:00Scientific vs. Legal Definitions of 'Drug' and 'Narcotic Drug'drug definition, narcotic drug, legal classification, pharmacology, neuroscience, psychedelic policy, controlled substances, scheduling, terminology, regulatory frameworkshttps://mindmedicinelaw.com/briefing/mental-health-symptoms-and-distress-risk-in-intensive-meditation-new-evidence-fr-20260930-46656The Psychedelic Journalen2026-10-04T15:06:37.658466+00:00Mental Health Symptoms and Distress Risk in Intensive Meditation: New Evidence from a Preregistered Studymeditation retreat safety, mental health screening, psychedelic risk assessment, matched-control clinical trial, depression and anxiety exclusion, non-ordinary states, distressing experiences, mindfulness meditation, preregistered study, clinical trial designhttps://mindmedicinelaw.com/briefing/self-medication-of-adhd-with-psychoactive-substances-evidence-and-framing-in-adu-20260930-46299The Psychedelic Journalen2026-10-03T15:06:20.482398+00:00Self-Medication of ADHD with Psychoactive Substances: Evidence and Framing in Adult Populationsadhd, self-medication hypothesis, psychoactive substances, adult mental health, substance use motives, nicotine and adhd, cannabis research, clinical screening, policy implications, harm reductionhttps://mindmedicinelaw.com/briefing/ketamine-s-antidepressant-and-anti-alcohol-mechanisms-in-aud-preprint-review-20260930-46336The Psychedelic Journalen2026-10-03T15:06:09.313608+00:00Ketamine’s Antidepressant and Anti-Alcohol Mechanisms in AUD: Preprint Reviewketamine, alcohol use disorder, mechanism of action, antidepressant effects, clinical trials, NMDA receptor, memory reconsolidation, preprint research, regulatory policyhttps://mindmedicinelaw.com/briefing/automated-home-cage-monitoring-in-mouse-models-implications-for-translational-ps-20260929-46658The Psychedelic Journalen2026-10-04T15:07:09.028280+00:00Automated Home-Cage Monitoring in Mouse Models: Implications for Translational Psychiatryautomated home-cage monitoring, mouse models, psychiatric research, preclinical trials, psychedelic drug development, translational validity, regulatory science, behavioral phenotyping, data harmonizationhttps://mindmedicinelaw.com/briefing/test-retest-study-validates-reliability-of-psychedelic-use-surveys-in-us-20260929-46630The Psychedelic Journalen2026-10-04T15:06:00.603129+00:00Test-Retest Study Validates Reliability of Psychedelic Use Surveys in USpsychedelic survey reliability, test-retest study, NSIHT, self-reported substance use, epidemiology, public health policy, Gwet's AC1, trend analysis, survey methodology, psychedelic researchhttps://mindmedicinelaw.com/briefing/emerging-drug-checking-technologies-in-canada-policy-and-practice-outlook-20260929-46315The Psychedelic Journalen2026-10-03T15:05:48.685040+00:00Emerging Drug-Checking Technologies in Canada: Policy and Practice Outlookdrug-checking technologies, harm reduction, canada drug policy, portable spectroscopy, novel psychoactive substances, public health surveillance, unregulated drug supply, implementation challenges, equity in healthcare, machine learning in drug analysishttps://mindmedicinelaw.com/briefing/adverse-outcomes-of-major-psychedelics-us-cross-sectional-data-20260929-46306The Psychedelic Journalen2026-10-03T15:05:24.680857+00:00Adverse Outcomes of Major Psychedelics: US Cross-Sectional Dataadverse events, psychedelics, psilocybin, LSD, MDMA, ibogaine, 5-MeO-DMT, public health, clinical risk, drug policyhttps://mindmedicinelaw.com/briefing/psilocybin-for-trd-phase-3-evidence-safety-and-eu-access-models-20260929-46307The Psychedelic Journalen2026-10-03T15:05:11.679127+00:00Psilocybin for TRD: Phase 3 Evidence, Safety, and EU Access Modelspsilocybin, treatment-resistant depression, phase 3 trials, safety concerns, germany compassionate use, eu regulation, clinical implementation, digital therapeutics, neuroplasticity, HPPDhttps://mindmedicinelaw.com/briefing/phase-1-results-oral-ketamir-2-safety-and-pk-in-healthy-adults-20260929-46338The Psychedelic Journalen2026-10-03T15:05:00.116882+00:00Phase 1 Results: Oral Ketamir-2 Safety and PK in Healthy Adultsketamir-2, nmda antagonist, phase 1 trial, neuropathic pain, oral administration, safety profile, pharmacokinetics, non-dissociative, psychoplastogen pipeline